

ESC Working 3 on Cardiovascular Pharmacology and Drug Therapy

Annual Report 2004/05

Objectives of the Working Group:

To promote and organise research in the field of cardiovascular pharmacology and drug therapy, to gather and exchange information regarding research and related activities within the Working Group, to organize teaching workshops on topics related to cardiovascular pharmacology and drug therapy, to hold regular meetings of the Working Group on specific topics, to be involved in task forces of the European Society of Cardiology related to cardiovascular pharmacology, to contribute to the organisation and preparation of the Annual Congress of the ESC, and to participate and support other scientific meetings and symposia

Number of Sessions organized by the Working Group at the ESC Congress 2005:

The Working #3 on Cardiovascular Pharmacology and Drug Therapy organises at the ESC Congress 2005 in Stockholm the following three Sessions:

Symposium: *Cardiovascular Clinical Trials - Close Inspection, Rearview*
Sunday, Sept 4, 2005: 08.30 – 10.00, room Paris (Blue Zone)

Chairpersons: Ferenc Follath (Zürich, CH), Faiez Zannad (Dommartin-les-Toul, FR)

K Dickstein (Stavanger, NO): Uses of trials for evidence-based cardiovascular medicine

H Wedel (Gothenburg, SE): How big a trial do we really need?

RM Califf (Durham, US): What have we learned from failed trials?

P Poole-Wilson (London, GB): How trials affect patients' and doctors' lives

S Yusuf (Hamilton, CD): Are industry sponsored trials addressing public health issues?

Debate Session: *Aldosterone antagonism: yesterday – today – tomorrow*
Sunday, Sept 4, 2005: 11:00 – 12:30, room Paris (Blue Zone)

Chairpersons: E Ambrosioni (Bologna, IT), D Atar (Oslo, NO)

Synthetic aldosterone inhibitors should replace spironolactone in modern heart failure therapy.

Pro: AD Struthers (Dundee, GB) – *Contra:* Henry Krum (Melbourne, Australia)

Beneficial effects of aldosterone inhibition override adverse effects such as hyperkalemia.

Pro: Faiez Zannad (Dommartin-les-Toul, FR) – *Contra:* Keld Kjeldsen (Copenhagen, DK)

Clinical Seminar: *Abuse of anabolic steroids in males and females engaged in sports*

Sunday, Sept 4, 2005: 14.00 – 15.30, room Paris (Blue Zone)

Chairpersons: D Corrado (Padua, IT), EE Solberg (Oslo, NO)

I Thiblin (Uppsala, SE): Cardiac pathology in autopsied users of anabolic androgenic steroids

A Urhausen (Luxembourg, LU): Are the cardiac effects of anabolic steroids reversible?

S Halvorsen (Oslo, NO): Anabolic steroid abuse and thrombosis

F Furlanello (San Donato, IT): Arrhythmogenic effects of anabolic steroids

Activities of the Working Group outside the ESC Congress:

The Working Group #3 on Cardiovascular Pharmacology and Drug Therapy organised an

Educational Autumn Meeting in Vienna, AT, November 27-28, 2004.

In addition, the Working Group was actively involved at the

Global Cardiovascular Clinical Trialists Forum, Cannes, FR, March 31st - April 2nd, 2005

Registries, Surveys:

During the period mentioned above, the Working #3 on Cardiovascular Pharmacology and Drug Therapy was not involved in Registries / Surveys.

Study Groups:

During the period mentioned above, the Working #3 on Cardiovascular Pharmacology and Drug Therapy was not involved in Study Groups.

Financial Situation:

As by March 2005, the actual balance of the Working #3 on Cardiovascular Pharmacology and Drug Therapy was € +4506,67

Dr Kurt Stoschitzky, FESC
(Secretary, ESC WG #3)

**Nucleus of the Working #3 on Cardiovascular Pharmacology and Drug
Therapy**
as by July 25, 2005

Chairman: E Ambrosioni, Bologna, IT

Vice-Chairman: D Atar, Oslo, NO

Treasurer: L Ruilope, Barcelona, SP

Secretary & Web Editor: K Stoschitzky, Graz, AT

Nucleus Members: F Follath, Zürich, CH

K Kjeldsen, Kobenhavn, DK

Ph Lechat, Paris, FR

B Prichard, London, UK

W van Gilst, Groningen, NL

F Zannad, Nancy, FR